ESPEROCT is a brand name for Antihemophilic Factor (Recombinant), PEGylated-exei, a biologic medication specifically designed for the treatment and management of Hemophilia A. Hemophilia A is a genetic disorder characterized by a deficiency in factor VIII, a protein essential for blood clotting. ESPEROCT works by replacing the missing or deficient factor VIII, thereby helping to control and prevent bleeding episodes. This recombinant, PEGylated form of factor VIII is engineered to have a longer half-life in the body compared to non-PEGylated forms, which means it can be administered less frequently while still effectively managing the condition. ESPEROCT is used in both adults and children and can be prescribed for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment, and control of bleeding, and in the perioperative management of patients.